You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Human Apyrase to Disrupt Cancer Therapy

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, al ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Software for Early Detection of Diabetic Neuropathy

    SBC: LICKENBROCK TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this SBIR Phase I research is to develop and test a software prototype. The prototype will lead to a software product. It will be a clinical tool that helps clinicians to assess the condition of pa tients who are at risk of or who have diabetic neuropathy. The software will analyze optically sectioned images of subbasal nerve fiber layers ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Dynamic ICG and FA Software

    SBC: LICKENBROCK TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Indocyanine Green (ICG) and Sodium Fluorescein (SF) are fluorescent dyes used clinically in eye fundus imaging, primarily for detecting vascular abnormalities in the retina and choroid, which is the layer behind the ret ina. It is used with the Heidelberg Retinal Tomograph (HRT) by visualizing movies that show the dynamics of the dye filling and draining throug ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Therapeutic Agents for Diabetic Ulcers

    SBC: AUXAGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetes mellitus afflicts 20.8 million people, or 7% of the population, in the United States. Fifteen percent, or 2.4 million people, will develop diabetic foot ulcers in their life time. Diabetic foot ulceration and i nfections are a major cause of hospitalization of diabetic patients. The direct and indirect costs of ulcer management and treatment exceed 10 ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Quantitative I-123 Cardiac SPECT using a Novel Spectral Fitting Method for High E

    SBC: CARDIOVASCULAR IMAGING TECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): Current emphasis on metabolic approaches and models for diagnosing heart disease have renewed development of 123I SPECT imaging agents applied in stand-alone protocols and as a complimentary role to existing stress/rest perfusion protocols. However, a majority of the current nuclear cardiology SPECT equipment base and associated infrastructure utilize low ener ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Macrofilaricidal Compounds: Target Identification and Chemical Optimizatio

    SBC: Divergence, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Parasitic infect over 140 million people, with up to one billion at risk in 80 countries. Lymphatic filariasis creates an enormous health and economic burden within affected areas and is the second leading cause of long -term disability. In 2000, international groups including the World Health Organization (WHO) launched an initiative to eliminate lymphatic fil ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Novel and Effective Antifungal Compounds Derived from Molecular Field Analysis

    SBC: Divergence, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Invasive fungal infections are an increasingly common and serious cause of illness and death in the U.S. and worldwide. Infection by Candida albicans has increased tenfold to become more frequent than diseases caused by E. coli and Pseudomonas, and it has become one of the most common fatal infections in the United States. Clinical management of invasive funga ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Development of High Temperature Cryopreservation Medium for Storage and Shipping

    SBC: IMPACT BIOLABS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): One of the most expensive aspects of a cryopreservation program is related to ongoing, long-term storage and shipping of samples at very low temperatures (typically between - 196oC, the temperature of liquid nitrogen (L N2), and approximately -120oC, in the high- end temperature range of LN2 vapor). Current approaches to cryopreserving most cells and tissues, i ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. SBIR TOPIC 252-COMMERCIALLY VIABLE SYNTHESIS OF MULTIFUNCTIONAL CANCER RECEPTOR

    SBC: NANOPARTICLE BIOCHEM, INC.            Topic: N/A

    In this Phase I SBIR contract, Nanoparticle Biochem Inc (NBI) proposes to develop commercially viable synthetic methodology for the production of multifunctional gold Nanoparticle-bombesin conjugate. Gold Nanoparticle-bombesin (AuNP-BBN) conjugate is a potential clinical imaging and therapeutic agent for the detection and treatment of GRP receptors over-expressing prostate and breast cancers. Aver ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. IN VIVO COMPATIBLE AND READILY INJECTABLE GOLD NANO CONSTRUCTS FOR TUMOR THERAPY

    SBC: NANOPARTICLE BIOCHEM, INC.            Topic: N/A

    The objective of this proposal is to develop nanoparticulate therapeutic products from the readily injectable Gold-198 (Au-198) nanoconstructs invented at the University of Missouri and licensed to Nanoparticle Biochem, Inc. The Phase I effort embodies three aims: (1) Optimization of synthetic protocols, large scale production, and quality control capabilities of Au-198 nanoparticles (NP) and thei ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government